These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 14678858)

  • 1. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes mellitus. Proceedings of a symposium. November 6-8, 2002, New York, New York, USA.
    Am J Med; 2003 Dec; 115 Suppl 8A():1S-120S. PubMed ID: 14678858
    [No Abstract]   [Full Text] [Related]  

  • 2. [How does the PROactive Study change therapy of diabetes?].
    Erdmann E
    MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
    [No Abstract]   [Full Text] [Related]  

  • 3. [Timely intervention with insulin sensitizer. Controlling cardiovascular risks].
    MMW Fortschr Med; 2003 Jun; 145(23):56-7. PubMed ID: 12854228
    [No Abstract]   [Full Text] [Related]  

  • 4. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.
    Dandona P; Aljada A
    J Diabetes Complications; 2004; 18(2):91-102. PubMed ID: 15120703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF; Lohray BB
    J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract]   [Full Text] [Related]  

  • 6. [New subgroup analysis of the PROactive Study. Risk for recurrent stroke cut in half].
    MMW Fortschr Med; 2006 Oct; 148(41):50-1. PubMed ID: 17190265
    [No Abstract]   [Full Text] [Related]  

  • 7. The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes.
    Pratley RE
    Curr Diab Rep; 2006 Feb; 6(1):45-6. PubMed ID: 16522280
    [No Abstract]   [Full Text] [Related]  

  • 8. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
    MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688
    [No Abstract]   [Full Text] [Related]  

  • 9. Rosiglitazone.
    Simon D
    Prim Care Diabetes; 2009 May; 3(2):123-4. PubMed ID: 19482530
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction: Symposium on diabetes, inflammation and cardiovascular disease.
    Smith U
    J Intern Med; 2007 Aug; 262(2):142-4. PubMed ID: 17645582
    [No Abstract]   [Full Text] [Related]  

  • 11. Actos and Avandia in type 2 diabetes. Where do they fit?
    Clark W
    Diabetes Self Manag; 2007; 24(4):8, 11-3. PubMed ID: 17663078
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular effects of the thiazolidinediones.
    Qayyum R; Schulman P
    Diabetes Metab Res Rev; 2006; 22(2):88-97. PubMed ID: 16184618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New studies, new strategies, new guidelines: so that diabetic patients will live longer].
    Aumiller J
    MMW Fortschr Med; 2005 Oct; 147(41):4-6. PubMed ID: 16270500
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
    Polonsky T; Mazzone T; Davidson M
    Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone: the future.
    Brunetti P
    Int J Clin Pract Suppl; 2001 Sep; (121):36. PubMed ID: 11594244
    [No Abstract]   [Full Text] [Related]  

  • 16. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidance on rosiglitazone for type 2 diabetes mellitus.
    Matthews DR
    Lancet; 2001 Feb; 357(9254):481. PubMed ID: 11273100
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pioglitazone. Review of its metabolic and systemic effects].
    Rodríguez Bernardino A; Cebrián Blanco S; Durán García S
    Rev Clin Esp; 2005 Dec; 205(12):610-20. PubMed ID: 16527183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
    Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
    Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
    Fonseca VA
    Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.